|View printer-friendly version|
Poster Discussion, Abstract # 368PD
Title: Dose Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activity of BGB-290 in Patients with Advanced Solid Tumors
Poster Discussion Session: Developmental Therapeutics
Date & Time:
Date & Time:
Location: Hall 8
Abstract # 387P: Desai, et al., Preliminary Results from Subsets of Patients (Pts) with Advanced Gastric Cancer (GC) and Esophageal Carcinoma (EC) in a Dose-Escalation/Expansion Study of BGB-A317, an Anti-PD-1 Monoclonal Antibody (mAb).
Abstract # 388P: Horvath, et al., Preliminary Results from a Subset of Patients (Pts) with Advanced Head and Neck Squamous Carcinoma (HNSCC) in a Dose-Escalation and Dose-Expansion Study of BGB-A317, an Anti-PD-1 Monoclonal Antibody (mAb).
Abstract # 389P: Meniawy, et al., Preliminary Results from a Subset of Patients (Pts) with Advanced Ovarian Cancer (OC) in a Dose-Escalation/Expansion Study of BGB-A317, an Anti-PD-1 Monoclonal Antibody (mAb).
Abstract # 420TiP: Johnson, et al., Phase 1b/2 Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide in Patients with Locally Advanced or Metastatic Solid Tumors.
Abstract # 421TiP: Wen, et al., Phase 1b/2 Study to Assess the Clinical Effects of BGB-290 in Combination with Radiation Therapy (RT) and/or Temozolomide (TMZ) in Patients with First-Line or Recurrent/Refractory Glioblastoma.
BGB-A317 is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. It is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. BGB-A317 has high affinity and specificity for PD-1. It is differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells. BGB-A317 is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
BGB-290 is a potent and highly selective inhibitor of PARP1 and PARP2 with pharmacological properties such as brain penetration and PARP–DNA complex trapping demonstrated in preclinical models. BGB-290 is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding clinical data of BGB-A317 or BGB-290. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including
Lucy Li, Ph.D. +1 781-801-1800 firstname.lastname@example.org email@example.com